MA44146A - Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer - Google Patents
Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancerInfo
- Publication number
- MA44146A MA44146A MA044146A MA44146A MA44146A MA 44146 A MA44146 A MA 44146A MA 044146 A MA044146 A MA 044146A MA 44146 A MA44146 A MA 44146A MA 44146 A MA44146 A MA 44146A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- combination
- treat cancer
- bispecific
- bispecific anti
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270749P | 2015-12-22 | 2015-12-22 | |
| PCT/US2016/068030 WO2017112775A1 (fr) | 2015-12-22 | 2016-12-21 | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44146A true MA44146A (fr) | 2018-10-31 |
| MA44146B1 MA44146B1 (fr) | 2023-10-31 |
Family
ID=57799835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44146A MA44146B1 (fr) | 2015-12-22 | 2016-12-21 | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20170174779A1 (fr) |
| EP (1) | EP3394103B1 (fr) |
| JP (1) | JP7126941B2 (fr) |
| KR (1) | KR20180089444A (fr) |
| CN (1) | CN108473578A (fr) |
| AU (1) | AU2016378721B2 (fr) |
| BR (1) | BR112018012801B1 (fr) |
| CA (1) | CA3009161A1 (fr) |
| DK (1) | DK3394103T3 (fr) |
| EA (1) | EA201891428A1 (fr) |
| ES (1) | ES2954153T3 (fr) |
| FI (1) | FI3394103T3 (fr) |
| HK (1) | HK1255040A1 (fr) |
| HR (1) | HRP20231156T1 (fr) |
| HU (1) | HUE063377T2 (fr) |
| IL (1) | IL259924A (fr) |
| LT (1) | LT3394103T (fr) |
| MA (1) | MA44146B1 (fr) |
| MD (1) | MD3394103T2 (fr) |
| MX (1) | MX2018007613A (fr) |
| PL (1) | PL3394103T3 (fr) |
| PT (1) | PT3394103T (fr) |
| RS (1) | RS64588B1 (fr) |
| SG (2) | SG11201804765UA (fr) |
| SI (1) | SI3394103T1 (fr) |
| WO (1) | WO2017112775A1 (fr) |
| ZA (1) | ZA201804681B (fr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| CA3211863A1 (fr) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Nouvelles proteines heterodimeres |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10544187B2 (en) | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| AU2015237184B2 (en) | 2014-03-28 | 2020-11-26 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
| CU24597B1 (es) | 2014-11-26 | 2022-05-11 | Xencor Inc | Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| CA3007030A1 (fr) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Anticorps heterodimees se liant a cd3 et psma |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| CN110603266A (zh) * | 2016-06-02 | 2019-12-20 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体 |
| WO2017218707A2 (fr) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Anticorps inhibiteurs de points de contrôle bispécifiques |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| US11020686B2 (en) | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| JP7142630B2 (ja) | 2016-10-14 | 2022-09-27 | ゼンコア インコーポレイテッド | ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質 |
| CN109923411B (zh) | 2016-10-25 | 2022-05-31 | 里珍纳龙药品有限公司 | 用于色谱数据分析的方法和系统 |
| BR112019010878A2 (pt) * | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| WO2018223004A1 (fr) * | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Anticorps bispécifiques se liant à cd20 et cd3 |
| AU2018276140A1 (en) | 2017-06-01 | 2019-12-19 | Compugen Ltd. | Triple combination antibody therapies |
| US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| RS63101B1 (sr) * | 2017-08-03 | 2022-04-29 | Amgen Inc | Interleukin-21 muteini i metode lečenja |
| TWI731264B (zh) | 2017-09-08 | 2021-06-21 | 美商安進公司 | Kras g12c抑制劑以及其使用方法 |
| CN116850284A (zh) * | 2017-09-20 | 2023-10-10 | 瑞泽恩制药公司 | 用于其肿瘤携带高过客基因突变负荷的患者的免疫治疗方法 |
| US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2019125732A1 (fr) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Protéines de fusion il-2 fc modifiées |
| EP3737694B1 (fr) * | 2018-01-12 | 2023-03-01 | Amgen Inc. | Anticorps anti-pd1 et méthodes de traitement |
| US20210069246A1 (en) * | 2018-01-31 | 2021-03-11 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
| EP3773911A2 (fr) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes |
| JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
| CA3097741A1 (fr) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Proteines de fusion heterodimeres ciblant tim-3 contenant des proteines de fusion fc d'il-15/il-15ra et domaines de liaison a l'antigene de tim-3 |
| TW202005985A (zh) * | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法 |
| TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| TWI822815B (zh) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | 抗-人類ｐｄ-ｌ１之抗體及其用途 |
| CN113195523A (zh) | 2018-10-03 | 2021-07-30 | Xencor股份有限公司 | IL-12异源二聚体Fc融合蛋白 |
| EP3874276B1 (fr) | 2018-10-31 | 2023-09-06 | Regeneron Pharmaceuticals, Inc. | Procédé et système d'identification et de quantification d'une protéine |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| CA3137361A1 (fr) | 2019-02-28 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau |
| WO2020180726A1 (fr) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Anticorps hétérodimères qui se lient à enpp3 et cd3 |
| EP3998081A4 (fr) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | Traitement du cancer hématologique avec une protéine à double spécificité pd-1/cd3 |
| SG11202110972UA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| KR20230082038A (ko) * | 2020-10-02 | 2023-06-08 | 리제너론 파마슈티칼스 인코포레이티드 | 사이토카인 방출 증후군을 저하하는 암 치료용 항체 조합 |
| EP3988568A1 (fr) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Traitement combiné |
| CN116963774A (zh) | 2021-01-28 | 2023-10-27 | 瑞泽恩制药公司 | 用于治疗细胞因子释放综合征的组合物和方法 |
| US20240076373A1 (en) | 2021-01-28 | 2024-03-07 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
| US20240082397A1 (en) | 2021-01-28 | 2024-03-14 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
| WO2022192403A1 (fr) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Anticorps hétérodimériques se liant à cd3 et à cldn6 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| CN114133449A (zh) * | 2021-12-14 | 2022-03-04 | 厦门大学附属第一医院 | 一种检测淋巴细胞表面pd-1受体的抗体组合物及其应用 |
| WO2023178192A1 (fr) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Anticorps antagonistes de l'il-18bp et leur utilisation en monothérapie et polythérapie dans le traitement du cancer |
| WO2023201226A1 (fr) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes permettant la destruction de cellule tumorale universelle |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| CA2508660C (fr) | 2002-12-23 | 2013-08-20 | Wyeth | Anticorps anti pd-1 et utilisations |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| CA2855098C (fr) | 2007-06-18 | 2018-02-27 | Merck Sharp & Dohme B.V. | Anticorps diriges contre le recepteur humain de mort programmee pd-1 |
| EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
| DK2350129T3 (en) | 2008-08-25 | 2015-08-31 | Amplimmune Inc | PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF |
| BR112013032552A2 (pt) | 2011-07-24 | 2017-12-12 | Curetech Ltd | variantes de anticorpos monoclonais humanizados imunomoduladores |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| PE20210107A1 (es) | 2013-12-17 | 2021-01-19 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
-
2016
- 2016-12-21 EA EA201891428A patent/EA201891428A1/ru unknown
- 2016-12-21 FI FIEP16826557.7T patent/FI3394103T3/fi active
- 2016-12-21 HR HRP20231156TT patent/HRP20231156T1/hr unknown
- 2016-12-21 SG SG11201804765UA patent/SG11201804765UA/en unknown
- 2016-12-21 DK DK16826557.7T patent/DK3394103T3/da active
- 2016-12-21 ES ES16826557T patent/ES2954153T3/es active Active
- 2016-12-21 PT PT168265577T patent/PT3394103T/pt unknown
- 2016-12-21 MX MX2018007613A patent/MX2018007613A/es unknown
- 2016-12-21 MD MDE20181060T patent/MD3394103T2/ro unknown
- 2016-12-21 JP JP2018532781A patent/JP7126941B2/ja active Active
- 2016-12-21 RS RS20230829A patent/RS64588B1/sr unknown
- 2016-12-21 AU AU2016378721A patent/AU2016378721B2/en active Active
- 2016-12-21 KR KR1020187017751A patent/KR20180089444A/ko active Search and Examination
- 2016-12-21 BR BR112018012801-5A patent/BR112018012801B1/pt active IP Right Grant
- 2016-12-21 HU HUE16826557A patent/HUE063377T2/hu unknown
- 2016-12-21 SI SI201631733T patent/SI3394103T1/sl unknown
- 2016-12-21 CA CA3009161A patent/CA3009161A1/fr active Pending
- 2016-12-21 CN CN201680075172.2A patent/CN108473578A/zh active Pending
- 2016-12-21 US US15/386,453 patent/US20170174779A1/en not_active Abandoned
- 2016-12-21 MA MA44146A patent/MA44146B1/fr unknown
- 2016-12-21 WO PCT/US2016/068030 patent/WO2017112775A1/fr active Application Filing
- 2016-12-21 PL PL16826557.7T patent/PL3394103T3/pl unknown
- 2016-12-21 LT LTEPPCT/US2016/068030T patent/LT3394103T/lt unknown
- 2016-12-21 EP EP16826557.7A patent/EP3394103B1/fr active Active
- 2016-12-21 SG SG10202005670TA patent/SG10202005670TA/en unknown
-
2018
- 2018-06-10 IL IL259924A patent/IL259924A/en unknown
- 2018-07-13 ZA ZA2018/04681A patent/ZA201804681B/en unknown
- 2018-11-06 HK HK18114163.2A patent/HK1255040A1/zh unknown
-
2021
- 2021-03-24 US US17/210,860 patent/US20210214457A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016378721B2 (en) | 2024-01-11 |
| AU2016378721A1 (en) | 2018-07-19 |
| EP3394103A1 (fr) | 2018-10-31 |
| ES2954153T3 (es) | 2023-11-20 |
| PL3394103T3 (pl) | 2023-11-20 |
| JP2019503361A (ja) | 2019-02-07 |
| PT3394103T (pt) | 2023-09-04 |
| HK1255040A1 (zh) | 2019-08-02 |
| IL259924A (en) | 2018-07-31 |
| BR112018012801A2 (pt) | 2018-12-04 |
| SG10202005670TA (en) | 2020-07-29 |
| MX2018007613A (es) | 2018-09-21 |
| SG11201804765UA (en) | 2018-07-30 |
| MD3394103T2 (ro) | 2023-11-30 |
| US20210214457A1 (en) | 2021-07-15 |
| FI3394103T3 (fi) | 2023-08-30 |
| RS64588B1 (sr) | 2023-10-31 |
| US20170174779A1 (en) | 2017-06-22 |
| MA44146B1 (fr) | 2023-10-31 |
| HUE063377T2 (hu) | 2024-01-28 |
| SI3394103T1 (sl) | 2023-10-30 |
| CA3009161A1 (fr) | 2017-06-29 |
| KR20180089444A (ko) | 2018-08-08 |
| HRP20231156T1 (hr) | 2024-01-05 |
| ZA201804681B (en) | 2019-04-24 |
| EP3394103B1 (fr) | 2023-06-28 |
| CN108473578A (zh) | 2018-08-31 |
| EA201891428A1 (ru) | 2018-12-28 |
| DK3394103T3 (da) | 2023-09-04 |
| WO2017112775A1 (fr) | 2017-06-29 |
| BR112018012801B1 (pt) | 2024-03-12 |
| LT3394103T (lt) | 2023-09-11 |
| JP7126941B2 (ja) | 2022-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44146A (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
| IL282962A (en) | Anti-PD-1 antibodies and methods of using them | |
| IL290295A (en) | A combination of antibodies against lag-3 and antibodies against pd-1 for the treatment of tumors | |
| HK1252857A1 (zh) | 抗cd3抗體及其使用方法 | |
| HK1259075A1 (zh) | Bcma抗體和其用以治療癌症和免疫病症的用途 | |
| MA44145A (fr) | Anticorps anti-cd20/anti-cd3 bispécifiques pour traiter la leucémie aiguë lymphoblastique | |
| MA43028A (fr) | Anticorps bispécifiques pour pd1 et tim3 | |
| MA43955A (fr) | Anticorps anti-bcma et anti-cd3 bispécifiques de format bite | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA43197A (fr) | Constructions d'anticorps bispécifiques pour cdh3 et cd3 | |
| SG11201704572UA (en) | Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases | |
| MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
| MA44391A (fr) | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 | |
| IL254529A0 (en) | A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer | |
| MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
| EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
| MA41097A (fr) | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses | |
| EA201791049A1 (ru) | Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы) | |
| IL283566A (en) | Antibody that binds vegf and il-1beta and methods of use | |
| MA44978A (fr) | Combinaison d'anticorps anti-pd-1 et de rayonnement pour traiter le cancer |